Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus casei Zhang
- Development stage
- Phase 4
- Lead developer
- Inner Mongolia Agricultural University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus casei Zhang is a specific probiotic strain isolated from traditional home-made koumiss (fermented horse milk) in Inner Mongolia, China. [9] It is being investigated for its potential health benefits, which primarily stem from its ability to modulate the gut microbiome. [13, 14] Research has shown that L. casei Zhang can mitigate gut dysbiosis, restore the population of beneficial bacteria that produce short-chain fatty acids (SCFAs) like butyrate, and increase levels of nicotinamide. [1, 2, 13] These effects lead to reduced inflammation and have shown potential in ameliorating kidney injury. [1] A Phase 1 clinical trial has suggested that it can slow the decline of kidney function in patients with chronic kidney disease. [1, 3] It is also under investigation for other conditions, including gout, hyperuricemia, and peritoneal fibrosis. [6, 13]
- Other names
- L. casei ZhangLactobacillus ZhangLac.zLacticaseibacillus casei Zhang
02
Targets
TLR2 (Toll-like Receptor 2)PPARG (Peroxisome proliferator-activated receptor gamma)RELA (Nuclear Factor Kappa B Subunit p65)TLR9 (Toll-like receptor 9)MEKTLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Lactobacillus casei Zhang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus casei Zhang.